Fierce Biotech

After unveiling a major restructuring initiative earlier this month, Genentech is sending 93 jobs in California to the chopping block.

Flagship Pioneering and Pfizer have added Quotient into their 10-program partnership, inking a deal to discover new targets for two programs in cardiovascular and renal diseases.

Join the global community of medtech innovators at The MedTech Conference in Toronto, October 15-17, 2024! Connect with industry leaders, explore cutting-edge innovations, and experience the brand-new Medtech Campus. This is your chance to network, collaborate, and stay ahead of the curve. 🔗 https://loom.ly/tkdocFs With over 400 subject matter experts leading 100+ dynamic sessions, our premier education program delivers unparalleled insights into the future of the industry. Combine that with ample networking opportunities, and it’s clear—this is an event you can’t afford to miss. Register today! 🔗 https://loom.ly/tkdocFs #mtc24 #medtechcon #medtechinmotion

The Fierce Pharma, Fierce Biotech and Fierce Healthcare teams are finalists for three Eddie & Ozzie Awards this year! The caliber of journalists on our team is truly impressive, and I’m always proud when their work is recognized. No reprieve for biopharma layoffs in Q1: Fierce Biotech analysis by Gabrielle Masson. (Analysis > B2B category): https://lnkd.in/d4UAq8CN The Fierce 50 of 2023 by the entire editorial team. This was a true team effort and a major undertaking. I’m incredibly proud of the 50 inspiring profiles featured in this project. (Profile or Q&A > B2B category): https://lnkd.in/dVb5wWhE This year's edition will go live in early September. And another great piece by Gabrielle Masson! Women left out of VC club fight for their identity, pulling each other up one by one (Single Article > B2B > Healthcare/Medical/Nursing category): https://lnkd.in/dCQZznkP

Indivior is picking up a small molecule allosteric modulator designed to treat substance use disorder from Addex Therapeutics, providing the latter the chance to make up to $300 million in biobucks, plus royalties.

Navigator Medicines has equipped itself with $100 million in series A funds as the young biotech charts a course for its newly acquired autoimmune drugs.

🚀 Drive Innovation at the Fierce Biotech Summit in Boston! Join Fierce Biotech editors and industry experts at the Fierce Biotech Summit in Boston (Sept. 30 - Oct. 1) as they tackle today’s biggest challenges in biotech. Gain exclusive insights into the recovery of the biotech industry, connect with the Fierce 15 honorees and network with over 500 biotech executives. Act fast—spots are filling up quickly: https://bit.ly/3AyapOg #FierceBiotech #FierceBiotechSummit #BiotechInnovation #StrategicPartnerships

Just days after gene editor Tome Biosciences announced undisclosed operational cuts, a clearer picture is coming into focus as 131 employees are being laid off.

VA medical centers are at the forefront of healthcare innovation. Researchers and executives can leverage groundbreaking VA inventions through technology transfer, saving time and money while developing new products and services for the healthcare market. 🔗 https://bit.ly/3TnyqOX TechLink, the VA’s official technology transfer partner, plays a crucial role in helping companies license impactful technologies that benefit both patients and providers. Discover how Xenex collaborated with the VA to create TrackMate—a revolutionary disinfection tracking tool for portable medical equipment designed to minimize infection spread. 🔗 https://bit.ly/3TnyqOX #Sponsored

After raising $213 million in 2023—one of the year’s largest private biotech rounds—gene editor Tome is making cuts.